Business context and reporting period
Filing identity: The request identifies Cypherpunk Technologies Inc., but the supplied 10-K is for Leap Therapeutics, Inc. (NASDAQ: LPTX), filed February 23, 2018. It reports the fiscal year ended December 31, 2017—not Q4-only results—and compares with fiscal 2016.
Leap is a clinical-stage biopharmaceutical company with no approved products and no product-sale revenue. Its lead candidates are DKN-01, an anti-DKK1 antibody, and TRX518, a GITR agonist antibody, both in oncology clinical development.
Financial performance, cash flow and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $22.5 million | $23.3 million |
| General and administrative expense | $9.8 million | $4.0 million |
| Operating loss | $32.4 million | $27.3 million |
| Net loss | $29.7 million | $25.6 million |
| Net cash used in operating activities | $22.1 million | $25.3 million |
| Cash and cash equivalents at year-end | $25.7 million | $0.8 million |
Gross profit and operating margins are not meaningful because the company had no product revenue. No cash debt remained at December 31, 2017; $30.3 million of related-party notes and accrued interest outstanding at the prior year-end converted to common stock in January 2017. The balance sheet reported total assets of $29.1 million, current assets of $27.7 million, current liabilities of $6.1 million, and a separate $11.9 million warrant liability.
Financing activities provided $47.8 million in 2017, including $21.2 million associated with the Macrocure merger, $10.0 million from a subscription agreement, and $18.0 million gross proceeds from a private placement. The company reported a $1.7 million Australian R&D incentive receivable. Management said cash plus expected incentive receipts should fund operations for at least 12 months from the financial-statement issuance date.
Material changes versus 2016
- Net loss increased $4.1 million, while operating expenses rose $5.0 million. G&A increased $5.8 million, chiefly from stock-based compensation, added staff and public-company insurance costs.
- R&D expense fell $0.8 million: DKN-01 spending rose $1.6 million to $15.3 million, while TRX518 spending fell $2.4 million to $7.2 million.
- Operating cash use declined by $3.2 million, but year-end cash rose substantially following merger-related and equity financing proceeds.
- Australian R&D incentive income declined $1.4 million to $1.7 million. Foreign currency results shifted from a $0.2 million loss to a $0.8 million gain.
- The Macrocure transaction, public listing and preferred-stock and related-party debt conversions substantially changed the capital structure. The November private placement included one warrant per share and resulted in a $11.9 million year-end warrant liability.
Outlook, clinical programs, risks and unusual items
- Outlook: Management expected continuing operating losses and rising expenses as development advances. Additional funding or collaboration cost-sharing will be needed; absent funding, the company may delay, reduce or eliminate trials or other programs. No financial revenue or earnings guidance is provided.
- Clinical progress: Preliminary, uncontrolled DKN-01 results included a 26% partial-response rate and 60% disease-control rate among 50 advanced esophageal/gastroesophageal-junction cancer patients receiving DKN-01 plus paclitaxel. In biliary tract cancer, 7 of 22 evaluable patients had partial responses and the reported disease-control rate was 96%; preliminary median progression-free survival was 9.4 months. These findings were not definitive and require confirmation. TRX518 multiple-dose monotherapy data showed stable disease as best response in 50% of patients as of August 2017; combination arms were enrolling.
- The filing anticipated further clinical data during 2018, including DKN-01 biliary tract cancer efficacy data, gynecologic-cancer interim data, and TRX518 follow-up and combination-arm data. Both candidates remained investigational and had not been submitted to FDA for approval.
- Key risks: Early-stage clinical outcomes may not be reproduced in larger or controlled trials; enrollment, regulatory review, manufacturing and third-party CRO/CMO execution could delay development. The company has no commercial infrastructure, relies on external manufacturers and faces larger competitors and substantial future financing needs.
- Other exposures: The private-placement warrants have full-ratchet anti-dilution provisions and are liability-classified using Level 3 valuation inputs. European patent opposition proceedings challenge two TRX518-related patents. A shareholder royalty vehicle is entitled to 5% of net sales of TRX518 products and 2% of net sales of DKN-01 products if commercialized. The filing also describes dilution risk from warrant exercise and future financing, and potential limits on tax-loss carryforwards.
- Management reported effective disclosure controls and internal control over financial reporting at year-end; the auditor did not provide an internal-control attestation because of the emerging-growth-company exemption. The financial-statement audit opinion was unqualified.
Important facts for investors to verify
- Confirm the issuer and ticker: the supplied filing is Leap Therapeutics (LPTX), not Cypherpunk Technologies Inc.
- Review the complete audited statements and notes for cash runway assumptions, current obligations, warrant-liability valuation and financing terms.
- Check subsequent clinical-trial updates and whether preliminary response and progression-free-survival results were confirmed in expanded or controlled studies.
- Track the timing and terms of additional capital raises, including potential dilution and the warrants’ full-ratchet adjustment provisions.
- Verify the status and potential consequences of the European TRX518 patent oppositions and the company’s Australian R&D incentive eligibility.